Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Laboratory consumables and reagents / Discovery and screening assay reagents for biotech and pharma research teams

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Discovery and screening assay reagents for biotech and pharma research teams

Single-use assay reagents, kits, plates, plasticware and general lab chemicals bought by discovery-stage biotechnology companies and the discovery/preclinical research groups of pharmaceutical companies to run screening, cell-based and biochemical assays in research workflows. Segmented by buyer organisation type (biotech and pharma R&D) and the job of generating experimental read-outs in discovery, not in regulated testing or scale-up. Excludes QC/contract testing (niche 3), scale-up purification (niche 2), clinical sample handling (niche 5) and grant-funded academic work (niche 4).

Market size
$12.0B
$12.0B ($9.6B–$14.4B) · 2026 · Bottom-up
Growth
+7.0%
$16.8B by 2031
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
3 sources · Bottom-up
Level
Niche
Segmented by
Customer type
Buyers
Biotechnology companies (discovery and preclinical research) and discovery research units of pharmaceutical companies
Buying centre
Head of discovery biology / assay development lead, supported by lab operations manager and a procurement or category buyer; technical evaluation typically run by the assay scientist who owns the protocol, with purchasing routed through central lab procurement or e-catalogue buyers
Buying triggers
  • Start of a new discovery programme or target, which opens a fresh reagent and consumable basket
  • Platform or assay technology transfer into the organisation (e.g. new screening modality adopted)
  • Re-validation or method change after assay failure, contamination event or supplier discontinuation
  • Annual budget reset and instrument upgrade cycles that force protocol re-specification
Pains
  • Long lead times and lot-to-lot variability in critical reagents disrupting multi-week assay timelines
  • Fragmented catalogue ordering across many SKUs with high freight and handling cost per order
  • Supplier-specific formulations that lock the lab into one vendor's protocol and packaging
  • Price increases on routine reagents with limited ability to qualify alternatives without re-qualification effort
Scores (1–5)
Pain intensity—
Purchasing power5
Reachability—
Growth—

How this was sized

$12.0B ($9.6B–$14.4B) · 2026 · Bottom-up

Parent pool for laboratory consumables and reagents, 2026: triangulated at USD 60.4B as Emergen life science tools & reagents 2026 USD 109.77B [3] x 55% assumed consumables-and-reagents share; cross-check GVR life science tools 2026 USD 202.6B [1] x 30% assumed consumables share = USD 60.8B. Parent range USD 48-72B from 45-65% and 25-35% share assumptions. Niche = parent x 20% assumed discovery-assay share = USD 12.1B, rounded to USD 12.0B; range USD 9.6-14.4B (parent range x 20%). Forecast: 12.0 x 1.07^5 = USD 16.8B by 2031, CAGR set below the 10.2% life science tools CAGR [1]/[7] because discovery consumables are more mature than instruments.

Alongside it in Laboratory consumables and reagents

// Sell into Discovery and screening assay reagents for biotech and pharma research teams

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.